Humacyte (NASDAQ:HUMA) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Friday morning, MarketBeat reports. They currently have a $15.00 price objective on the stock, up from their prior price objective of $12.00.

HUMA has been the subject of several other research reports. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Benchmark reissued a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Finally, TD Cowen reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $13.43.

Humacyte Trading Up 34.1 %

HUMA opened at $4.64 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 52 week low of $2.48 and a 52 week high of $9.97. The stock has a market cap of $583.99 million, a PE ratio of -3.46 and a beta of 1.38. The business has a 50 day moving average of $4.83 and a 200-day moving average of $5.83.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. nVerses Capital LLC bought a new position in shares of Humacyte during the 2nd quarter valued at $28,000. Concurrent Investment Advisors LLC bought a new position in Humacyte in the third quarter valued at about $75,000. Principal Financial Group Inc. purchased a new position in Humacyte in the second quarter worth about $83,000. FORA Capital LLC bought a new stake in shares of Humacyte during the 3rd quarter valued at about $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $97,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.